Advances of Antibody-Drug Conjugates Targeting Trop-2 in the Treatment of Breast Cancer
Trophoblast cell surface antigen 2(Trop-2)exhibits underexpression in normal tissue,yet overexpression in many tumor tissues.The overexpression of Trop-2 plays a significant role in the initiation,progression,and metastasis of tumor.With the significant breakthrough of sacituzumab govitecan,anti-Trop-2 antibody-drug conjugate(ADC),in treating advanced triple-negative breast cancer,along with its approved indications and the recent positive findings from various phase Ⅲ clinical trials regarding ADC targeting Trop-2,the development of ADC targeting Trop-2 has become a promising new strategy for tumor treatment.This review provides a comprehensive overview of the structure and function of Trop-2,the recent advances in clinical research regarding ADC targeting Trop-2 for breast cancer and the existing challenges,aiming to offer some valuable insight for the selection of therapeutic strategies for breast cancer patients.
NETL
NSTL
万方数据
